Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911167 | 0.86 | KMT2A (0.51) | CYP3A4SMN1; SMN2DHFRSOD1KDM4E | |
| SCHEMBL3207718 | 0.85 | GGPS1 (0.50) | DHFRTHRBTSHRCYP2D6 | |
| SCHEMBL910726 | 0.83 | CHRM2 (0.55) | CYP3A4TP53CHRM2CHRM1CHRM3 | |
| SCHEMBL2294721 | 0.82 | TP53 (0.50) | CYP3A4TP53CHRM2CHRM1CHRM3 | |
| SCHEMBL362937 | 0.81 | TAAR1 (0.59) | CHRM2CHRM1CHRM3SMN1; SMN2ALDH1A1 | |
| SCHEMBL2702132 | 0.81 | TRIM24 (0.44) | ALDH1A1MAPTMAPK1TSHRHTT | |
| SCHEMBL2675382 | 0.81 | MAOB (0.61) | SMN1; SMN2KDM4EALDH1A1GAAMAPT | |
| SCHEMBL4353971 | 0.79 | CHRM2 (0.58) | CYP3A4TP53CHRM2CHRM1CHRM3 | |
| SCHEMBL7002579 | 0.79 | CHRM2 (0.48) | CYP3A4TP53CHRM2CHRM1CHRM3 | |
| SCHEMBL11197522 | 0.79 | PPARA (0.51) | CYP3A4TP53CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | claimed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | claimed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | claimed |
| CN-102319184-B | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| EP-2420491-B1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-4065618-A | Process for 3-H-3-cephem esters | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4065621-A | Process for 3-alkyl and 3-phenyl cephalosporins | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4064343-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-4013651-A | 3-SUBSTITUTED AMINO-CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3992377-A | 3-Thio-substituted cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3985737-A | ANTIBACTERIAL AGENTS | ELI LILLY AND COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962227-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3960844-A | Preparation of 6-acylamino-2-methyl-2-halomethyl penams | ELI LILLY AND COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | CYP3A4 424/4885TP53 3827/4885CHRM2 1252/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | CYP3A4 4084/4885TP53 494/4885CHRM2 4853/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CYP3A4 4511/4885TP53 4030/4885CHRM2 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.